In vitro studies showed that ivacaftor was indeed able to potentiate CFTR in F508del HBE cultures [181]; however, clinical studies of CF homozygous for F508del patients showed that the ivacaftor treatment was not associated with significant clinical benefits [182]. This evidence concerns the gene CFTR and cystic fibrosis.